Apyx Medical 2025 Q2 Earnings Narrowed Losses with 43.2% Net Income Improvement

Apyx Medical (APYX) reported its fiscal 2025 Q2 earnings on August 8, 2025. The company narrowly its losses and raised full-year revenue guidance, though revenue declined year-over-year. The updated guidance reflects strong early demand for its AYON product and international expansion progress.

Revenue
Total revenue for Apyx Medical declined 6.4% year-over-year to $11.37 million in Q2 2025, compared to $12.15 million in the same period of the prior year. The Advanced Energy segment contributed $9.67 million, forming the core of the company’s revenue, while the OEM segment added $1.70 million. The Corporate & Other segment reported $0 in revenue, consistent with the company’s ongoing strategic focus on its core businesses.

Earnings/Net Income
Apyx Medical significantly narrowed its losses, with net income improving by 43.2% to a net loss of $-3.74 million in Q2 2025, down from $-6.59 million in Q2 2024. On a per-share basis, the company’s loss decreased to $0.09 from $0.19, representing a 52.6% improvement. Despite this progress, Apyx has posted losses in 13 consecutive fiscal quarters, underscoring the need for sustained performance improvements. The narrowing of losses is a positive step, but the persistent negative net income remains a concern.

Price Action
The stock price of Apyx Medical has experienced mixed performance recently, declining 5.77% during the latest trading day. However, it gained 2.62% over the past full trading week. Month-to-date, the stock has fallen 17.30%, indicating ongoing volatility in investor sentiment.

Post-Earnings Price Action Review
A strategy of buying Apyx shares immediately following quarterly earnings reports and holding for 30 days has historically delivered strong medium-term returns. Over three years, this approach has yielded a total return of 12.8%, with 14.5% and 13.2% returns over one year and six months, respectively. While the 30-day holding period occasionally introduces short-term volatility, the overall trend reflects a positive market reaction to earnings improvements and revised guidance. These returns suggest that the market is responding favorably to Apyx’s progress, particularly in areas such as product launches and revenue guidance upgrades.

CEO Commentary
Charlie Goodwin, President and CEO, expressed confidence in Apyx’s future, highlighting the successful commercial launch of AYON and strong physician interest in Renuvion’s debut in China. The CEO emphasized the potential for AYON to become a standard-of-care solution for loose skin post-weight loss and expressed optimism about the product’s market opportunity. Goodwin also underscored the leadership team’s capability to drive long-term sales growth in both domestic and international markets.

Guidance
Based on strong pre-orders for AYON, Apyx Medical raised its full-year 2025 revenue guidance to a range of $50.0 million to $52.0 million. This revision reflects the early success of AYON and progress in international markets, particularly China, where Renuvion is set for commercial launch.

Additional News
Recent global developments include heightened tensions over the Gaza conflict, with rifts emerging ahead of cabinet meetings in several countries. India pushed back against recent tariff hikes, while the United States and China were highlighted for their role in underpinning global stability. Political developments in Taiwan and Southeast Asia also drew attention, particularly a failed recall vote for Lai and the DPP. In the U.S., Trump continued to shape economic policy by nominating key advisers and adjusting immigration and census policies. Meanwhile, the EU faced mounting pressure from U.S. tariffs, and African nations turned to gold to stabilize financial systems. In the Middle East, humanitarian conditions in Gaza worsened as famine spread and peace talks stalled.